Impairment of approx. EUR 26 million in Sempermed segment

Vienna, Austria, 27 July 2017, 14:41 h — On 10 April 2017, Semperit AG Holding announced in accordance with Article 17 of the EU Market Abuse Regulation that the long-term earnings outlook for the Sempermed segment (Medical Sector) had to undergo a critical review compared with the previous assessment, which could result in a significant impairment in the Sempermed segment.

Following an in-depth review, the Management Board of Semperit AG Holding has come to the conclusion today that the sustainably achievable production volume at the site in Kamunting, Malaysia, is lower than previously assumed. As a result, an impairment of approximately EUR 26 million has to be recognised in the interim consolidated financial statements as of 30 June 2017. Thus, based on current knowledge, the goodwill of the segment will be completely impaired.

The exact amount of the impairment will be announced with the publication of the half-year financial report 2017 on 17 August 2017.

About Semperit
The publicly listed company Semperit AG Holding is an internationally-oriented group that develops, produces, and sells highly specialised rubber and plastic products in more than 100 countries for the medical and industrial sectors: examination and surgical gloves, hydraulic and industrial hoses, conveyor belts, escalator handrails, construction profiles, cable car rings, and products for railway superstructures. The headquarters of this traditional Austrian company, which was founded in 1824, are located in Vienna. The Semperit Group employs around 7,000 people worldwide, including close to 3,900 in Asia and more than 800 in Austria (Vienna and production site in Wimpassing, Lower Austria). The group has 22 manufacturing facilities worldwide and numerous sales offices in Europe, Asia, Australia and America. In 2016, the group generated sales of EUR 852 million and EBITDA of EUR 78 million.